SEC Comment Letter 0000000000-25-003412 to Neurogene Inc. (NGNE)
Neurogene Inc.
Date: March 31, 2025 · CIK: 0001404644 · Accession: 0000000000-25-003412
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286057
Letter
Re: Neurogene Inc. Registration Statement on Form S-3 Filed March 24, 2025 File No. 333-286057 Dear Rachel McMinn:
March 31, 2025
Rachel McMinn Chief Executive Officer Neurogene Inc. 535 W 24th St. 5th Floor New York, NY 10011
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Branden C. Berns
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 31, 2025 Rachel McMinn Chief Executive Officer Neurogene Inc. 535 W 24th St. 5th Floor New York, NY 10011 Re: Neurogene Inc. Registration Statement on Form S-3 Filed March 24, 2025 File No. 333-286057 Dear Rachel McMinn: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Branden C. Berns </TEXT> </DOCUMENT>